» Articles » PMID: 21423807

Carcinoma-derived Interleukin-8 Disorients Dendritic Cell Migration Without Impairing T-cell Stimulation

Abstract

Background: Interleukin-8 (IL-8, CXCL8) is readily produced by human malignant cells. Dendritic cells (DC) both produce IL-8 and express the IL-8 functional receptors CXCR1 and CXCR2. Most human colon carcinomas produce IL-8. IL-8 importance in malignancies has been ascribed to angiogenesis promotion.

Principal Findings: IL-8 effects on human monocyte-derived DC biology were explored upon DC exposure to recombinant IL-8 and with the help of an IL-8 neutralizing mAb. In vivo experiments were performed in immunodeficient mice xenografted with IL-8-producing human colon carcinomas and comparatively with cell lines that do not produce IL-8. Allogenic T lymphocyte stimulation by DC was explored under the influence of IL-8. DC and neutrophil chemotaxis were measured by transwell-migration assays. Sera from tumor-xenografted mice contained increasing concentrations of IL-8 as the tumors progress. IL-8 production by carcinoma cells can be modulated by low doses of cyclophosphamide at the transcription level. If human DC are injected into HT29 or CaCo2 xenografted tumors, DC are retained intratumorally in an IL-8-dependent fashion. However, IL-8 did not modify the ability of DC to stimulate T cells. Interestingly, pre-exposure of DC to IL-8 desensitizes such cells for IL-8-mediated in vitro or in vivo chemoattraction. Thereby DC become disoriented to subsequently follow IL-8 chemotactic gradients towards malignant or inflamed tissue.

Conclusions: IL-8 as produced by carcinoma cells changes DC migration cues, without directly interfering with DC-mediated T-cell stimulation.

Citing Articles

Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment.

Awasthi D, Sarode A Int J Mol Sci. 2024; 25(5).

PMID: 38474175 PMC: 10932322. DOI: 10.3390/ijms25052929.


Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer.

Xiao L, Su Y, Huang S, Chen Y, Hsueh P Int J Mol Sci. 2023; 24(21).

PMID: 37958973 PMC: 10648396. DOI: 10.3390/ijms242115990.


Bioinformatic Analysis of the CXCR2 Ligands in Cancer Processes.

Korbecki J, Bosiacki M, Chlubek D, Baranowska-Bosiacka I Int J Mol Sci. 2023; 24(17).

PMID: 37686093 PMC: 10487711. DOI: 10.3390/ijms241713287.


The synergistic and enhancive effects of IL-6 and M-CSF to expand and differentiate functional dendritic cells from human monocytes under serum-free condition.

Yao C, Tseng T J Biol Eng. 2023; 17(1):6.

PMID: 36703209 PMC: 9881386. DOI: 10.1186/s13036-023-00325-z.


Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.

Lemech C, Dredge K, Bampton D, Hammond E, Clouston A, Waterhouse N J Immunother Cancer. 2023; 11(1).

PMID: 36634920 PMC: 9843174. DOI: 10.1136/jitc-2022-006136.


References
1.
Murillo O, Dubrot J, Palazon A, Arina A, Azpilikueta A, Alfaro C . In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol. 2009; 39(9):2424-36. DOI: 10.1002/eji.200838958. View

2.
Ueda T, Shimada E, Urakawa T . Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994; 29(4):423-9. DOI: 10.1007/BF02361238. View

3.
Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A . The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med. 2008; 205(5):1155-71. PMC: 2373847. DOI: 10.1084/jem.20072509. View

4.
Martin-Fontecha A, Lanzavecchia A, Sallusto F . Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol. 2008; (188):31-49. DOI: 10.1007/978-3-540-71029-5_2. View

5.
Baggiolini M, Loetscher P . Chemokines in inflammation and immunity. Immunol Today. 2000; 21(9):418-20. DOI: 10.1016/s0167-5699(00)01672-8. View